ACADIA Pharmaceuticals Inc.
ACAD
Rang in Aktien
#4508
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Aktienkurs
$19.76
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$3.40B
Veränderung (1 Tag)
3.32%
Veränderung (1 Jahr)
-5.66%
Land
US
Handel ACADIA Pharmaceuticals Inc. (ACAD)
Kategorie
Healthcare
Gewinn für ACADIA Pharmaceuticals Inc. (ACAD)
Gewinn im Jun 2026 TTM: $121.37M
Laut den aktuellen Finanzberichten von ACADIA Pharmaceuticals Inc. betragen die aktuellen Gewinne des Unternehmens $121.37M. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $-51.04M, eine Steigerung gegenüber dem Gewinn im Jahr 2022, der $-213.44M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von ACADIA Pharmaceuticals Inc. von 2000 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $121.37M | -52.97% |
| 2024 | $258.08M | -605.67% |
| 2023 | $-51.04M | -76.09% |
| 2022 | $-213.44M | 27.41% |
| 2021 | $-167.52M | -40.38% |
| 2020 | $-280.97M | 19.88% |
| 2019 | $-234.38M | -3.92% |
| 2018 | $-243.94M | -15.38% |
| 2017 | $-288.28M | 6.75% |
| 2016 | $-270.05M | 64.55% |
| 2015 | $-164.11M | 77.47% |
| 2014 | $-92.48M | 143.69% |
| 2013 | $-37.95M | 82.01% |
| 2012 | $-20.85M | -8.42% |
| 2011 | $-22.77M | -250.37% |
| 2010 | $15.14M | -133.53% |
| 2009 | $-45.15M | -29.73% |
| 2008 | $-64.24M | 13.93% |
| 2007 | $-56.39M | 25.18% |
| 2006 | $-45.05M | 31.97% |
| 2005 | $-34.14M | 31.71% |
| 2004 | $-25.92M | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $5.27B | 4,246.20% |
US
|
|
| $-3.09B | -2,643.50% |
US
|
|
| $-4.02B | -3,409.11% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,507.22% |
NL
|
